TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1898640

Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 6218815

Group type: EXPERIMENTAL
Intervention: 5% (w/v) benzoyl peroxide gel
Number of subjects: 94

Group type: COMPARATOR
Intervention: 1.5% (w/v) erythromycin lotion
Number of subjects: 94
Study: 30366513

Group type: EXPERIMENTAL
Intervention: Positive Psychology (PP) intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 25
Study: 28948436

Group type: EXPERIMENTAL
Intervention: FAACT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: FACIT-F
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trial Outcome Index (TOI)
Number of subjects: 96
Study: 29574075

Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)Rx
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 26631116

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone (PAN‐BTZ‐Dex)
Number of subjects: 825
Study: 23225539

Group type: EXPERIMENTAL
Intervention: Amitriptyline (high-dose level)
Number of subjects: 0
Study: 21858807

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals)
Number of subjects: 0
Study: 20048654

Group type: EXPERIMENTAL
Intervention: Single-injection ultrasound-guided infraclavicular block
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Double-injection ultrasound-guided infraclavicular block
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the single-injection group)
Number of subjects: 88
Study: 16859992

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 75
Study: 15906589

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine formulation A (21 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine formulation B (21 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study: 12034157

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization system (CRS) consisting of a pulse generator interfaced with an atrio-biventricular lead system.
Number of subjects: 103
Study: 9861122

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg i.v. followed by infusion at a rate of 90 mg/15.5 h
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg followed by infusion of 75 mg/15.5 h
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg followed by infusion of 100 mg/15.5 h
Number of subjects: 85
Study: 7542132

Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Score (IPSS)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: IPSS
Number of subjects: 502
Study: 2194687

Group type: EXPERIMENTAL
Intervention: sulfamethoxazole + trimethoprim
Number of subjects: 614

Group type: COMPARATOR
Intervention: procaine penicillin
Number of subjects: 614
Study: 6173516

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30768393

Group type: EXPERIMENTAL
Intervention: Active Trigeminal Nerve Stimulation (TNS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham Trigeminal Nerve Stimulation (TNS)
Number of subjects: 62
Study: 28403832

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care (GPNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual prenatal care (IPNC)
Number of subjects: 0
Study: 25727941

Group type: EXPERIMENTAL
Intervention: Corn silk aqueous extract (60, 130, 192.5 and 260 mg/kg body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 40
Study: 24773287

Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic exercise (4 × 4 min at 85% HRR and 2 min at 60% HRR) for 30 min
Number of subjects: 29

Group type: COMPARATOR
Intervention: Moderate continuous aerobic exercise (70% HRR) for 30 min
Number of subjects: 29
Study: 23077059

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (dlPFC) during a voluntary forgetting task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued to forget previously studied information
Number of subjects: 0
Study: 19046326

Group type: EXPERIMENTAL
Intervention: CAF+CTG
Number of subjects: 85

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 85
Study: 17238221

Group type: EXPERIMENTAL
Intervention: Current drug treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative hypothetical drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No preventive medication
Number of subjects: 0
Study: 16524633

Group type: EXPERIMENTAL
Intervention: DAHANCA toxicity scoring system
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: EORTC QLQ
Number of subjects: 116
Study: 14667152

Group type: EXPERIMENTAL
Intervention: Intermittent bright light (approximately 5000 lux, 20 min on, 40 min off, 4‐5 light pulses/night)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Darker sunglasses during daytime commute
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Melatonin (1.8 mg sustained release)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Normal sunglasses during daytime commute
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dim light (approximately 150 lux) during night shift
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination of intermittent bright light, dark sunglasses, and regular early daytime dark/sleep period
Number of subjects: 67
Study: 10612322

Group type: EXPERIMENTAL
Intervention: Statin drug treatment
Number of subjects: 30817
Study: 8777119

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 1647183

Group type: COMPARATOR
Intervention: vindesine plus cisplatin (VP)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: mitomycin plus vindesine and cisplatin (MVP)
Number of subjects: 126
Study: 6144522

Group type: EXPERIMENTAL
Intervention: Clorazepate 15 mg nocte
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg t.d.s.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 100
Study: 29986721

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child safety control
Number of subjects: 0
Study: 27484801

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy plus trastuzumab, lapatinib or both
Number of subjects: 121
Study: 26162993

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells (WJMSCs)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 23412022

Group type: EXPERIMENTAL
Intervention: Cosmetic slimming treatment (twice a day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20303209

Group type: EXPERIMENTAL
Intervention: Closed treatment with rigid maxillomandibular fixation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 32
Study: 18343302

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: K-wire stabilization
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Volar plating with fixed-angle screws
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Fracture stabilization with locking volar plates
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Pins and plaster, bone cement, open reduction and internal fixation with plates
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Low-demand group
Number of subjects: 410
Study: 15708387

Group type: EXPERIMENTAL
Intervention: Ivermectin high dose (800 microg/kg) given three-monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin standard dose (150 microg/kg) given annually
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin high dose (800 microg/kg) given annually
Number of subjects: 0
Study: 12906959

Group type: EXPERIMENTAL
Intervention: Two simultaneously consumed 400 microg OTFC doses
Number of subjects: 12

Group type: COMPARATOR
Intervention: One 800 microg OTFC dose
Number of subjects: 12
Study: 10543484

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HC), n = 14
Number of subjects: 29

Group type: COMPARATOR
Intervention: Uncoated circuits (NHC), n = 15
Number of subjects: 29
Study: 8912225

Group type: EXPERIMENTAL
Intervention: Noradrenaline acid tartrate (0.33‐33.33 ng min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cumulative dose-response curve
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Noncumulative dose-response curve
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Noradrenaline application
Number of subjects: 12
Study: 1841573

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Serologic studies (antinuclear antibody test, fluorescent treponemal antibody absorption test)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Chest roentgenography
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 448
Study: 6354078

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ceforanide
Number of subjects: 85
Study: 31187261

Group type: EXPERIMENTAL
Intervention: Iron picolinate (2.5 mg 57Fe per serving, two servings)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Iron sulfate (2.5 mg 54Fe per serving, two servings)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relative bioavailability of Fe picolinate versus Fe sulfate
Number of subjects: 19
Study: 30378695

Group type: EXPERIMENTAL
Intervention: Alpinia officinarum extract (300 mg daily for 3 months)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 28431133

Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 856

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 856

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 856
Study: 26629352

Group type: EXPERIMENTAL
Intervention: Proteinuria <0.7 g/day after 12 months of treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Addition of urine red blood cells <5/hpf as response criteria at month 12
Number of subjects: 90
Study: 23703361

Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 110

Group type: COMPARATOR
Intervention: Circular multipolar duty‐cycled radiofrequency-based pulmonary vein ablation catheter (PVAC)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 21209240

Group type: EXPERIMENTAL
Intervention: diltiazem XR for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: diltiazem XR for 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: diltiazem CR for 2 days
Number of subjects: 0
Study: 19747623

Group type: EXPERIMENTAL
Intervention: High-Se Baker's yeast (300 microg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-Se yeast
Number of subjects: 42
Study: 17210735

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 10
Study: 15522771

Group type: EXPERIMENTAL
Intervention: Endogenous task shift in RRMS patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non‐brain damaged controls (NBDC)
Number of subjects: 22
Study: 10705194

Group type: EXPERIMENTAL
Intervention: Implantable impulse generator (n = 21)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conservative management (n = 23)
Number of subjects: 44
Study: 9089552

Group type: COMPARATOR
Intervention: CFT performed at various environmental temperatures with a Wet Bulb Globe Test (WBGT) greater than 25 degrees C
Number of subjects: 0
Study: 1492007

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 126

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 126
Study: 4041332

Group type: EXPERIMENTAL
Intervention: LA propranolol 160 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LA propranolol 320 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LA propranolol 160 mg and 320 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31117234

Group type: EXPERIMENTAL
Intervention: NIRS-based clinical algorithm activated when rScO2 dropped below threshold
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group with blind monitoring of rScO2
Number of subjects: 34
Study: 27974693

Group type: EXPERIMENTAL
Intervention: Nimotuzumab with concurrent chemotherapy and radiotherapy
Number of subjects: 23
Study: 26420450

Group type: EXPERIMENTAL
Intervention: Web-based information guide
Number of subjects: 16000

Group type: COMPARATOR
Intervention: General information about rehabilitation
Number of subjects: 16000
Study: 24186878

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 272
Study: 21355923

Group type: EXPERIMENTAL
Intervention: Excessive drinkers
Number of subjects: 3694

Group type: EXPERIMENTAL
Intervention: Consumers
Number of subjects: 3694

Group type: COMPARATOR
Intervention: Abstainers
Number of subjects: 3694
Study: 19966341

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to INR 2.0 to 3.0)
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2539
Study: 17846332

Group type: EXPERIMENTAL
Intervention: Processed cardiotomy blood (centrifugal washing and lipid filtration)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Unprocessed cardiotomy blood (control)
Number of subjects: 266
Study: 15202794

Group type: EXPERIMENTAL
Intervention: New cardiac troponin I (cTnI) assay (Access AccuTnI, Beckman Coulter)
Number of subjects: 106
Study: 11687324

Group type: EXPERIMENTAL
Intervention: Group learning programme
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 10567779

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg, p.o., once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8584455

Group type: EXPERIMENTAL
Intervention: Spirulina fusiformis (1 g/day for 12 months)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 2355813

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All groups (including diltiazem, placebo, and propranolol)
Number of subjects: 52
Study: 159068

Group type: EXPERIMENTAL
Intervention: Hafnia A anaesthetic system
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hafnia D anaesthetic system
Number of subjects: 16
Study: 31511278

Group type: EXPERIMENTAL
Intervention: Continuum-of-care intervention package
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1490
Study: 28705248

Group type: EXPERIMENTAL
Intervention: 10% imidacloprid/4.5% flumethrin polymer matrix collar (G1)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Untreated group (G2)
Number of subjects: 204
Study: 25681068

Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg intravenous (i.v.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dalbavancin 1500 mg intravenous (i.v.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo intravenous (i.v.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg oral
Number of subjects: 200
Study: 23412942

Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Dropouts
Number of subjects: 179

Group type: COMPARATOR
Intervention: Completers
Number of subjects: 179
Study: 21733508

Group type: EXPERIMENTAL
Intervention: Metformin plus combined hormonal oral contraceptive (OC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: OC plus matched placebo
Number of subjects: 19
Study: 19910719

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16731290

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual blood pressure control
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Low blood pressure control
Number of subjects: 1094
Study: 14609531

Group type: EXPERIMENTAL
Intervention: Ginger extract (Zintona EC) 250 mg of Zingiberis Rhizoma per capsule, qid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (identical looking capsules)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ginger extract (Zintona EC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10824663

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study: 8876341

Group type: EXPERIMENTAL
Intervention: Creatine-glucose mixture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose powder (placebo)
Number of subjects: 18
Study: 1857251

Group type: EXPERIMENTAL
Intervention: Icons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narrative text, table, pie chart
Number of subjects: 0
Study: 6574531

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3963032

Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buspirone (all doses)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Buspirone and Diazepam
Number of subjects: 19
Study: 29325064

Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 40
Study: 27281061

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 262
Study: 24884455

Group type: EXPERIMENTAL
Intervention: Neuromuscular training and muscle strengthening (12 sessions to strengthen knee extensors, hip abductors, and lateral rotators)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Neuromuscular training and muscle strengthening
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (12 sessions to strengthen hip and knee muscles)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 22240397

Group type: EXPERIMENTAL
Intervention: Recombinant ApfA alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: rApxIVA or rTbpB alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tri‐antigen combination of rApxIA, rApxIIA and rApxIIIA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penta‐antigen mixture of rApxIA, rApxIIA, rApxIIIA, rApxIVA and rTbpB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexa‐antigen vaccine containing rApfA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization with rApfA alone or in combination with other antigens
Number of subjects: 0
Study: 20175977

Group type: EXPERIMENTAL
Intervention: tramadol/acetaminophen 37.5 mg/325 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg bid
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 18771003

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg, q.d. (multiple doses)
Number of subjects: 0
Study: 15976587

Group type: EXPERIMENTAL
Intervention: Microchannel lens (MC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard hydrogel lens design (STD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Microchannel lens (MC) and Standard hydrogel lens design (STD)
Number of subjects: 15
Study: 12524662

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement for 40 weeks
Number of subjects: 0
Study: 10783995

Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine (500 mg/kg body weight/120 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 9031710

Group type: EXPERIMENTAL
Intervention: Breathing Pattern Training (BPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (traditional rehabilitation program only)
Number of subjects: 20
Study: 10146939

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine slow release (SR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study: 6835887

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone 2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hyoscine 1.6 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8